三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

已收盘 02-05 16:00:00 EST

149.04

-18.26

-10.91%

盘后147.66

-1.38-0.93%

19:59 EST

最高172.80	最低147.46	成交量76.30万
今开164.43	昨收167.30	日振幅15.15%
总市值5.18亿	流通市值5.18亿	总股本347.45万
成交额1.22亿	换手率21.96%	流通股本347.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":149.04,"timestamp":1770325200000,"preClose":167.3,"halted":0,"volume":763022,"hourTrading":{"tag":"盘后","latestPrice":147.66,"preClose":149.04,"latestTime":"19:59 EST","volume":11970,"amount":1775237.776,"timestamp":1770339546098,"change":-1.38,"changeRate":-0.009259,"amplitude":0.022209},"delay":0,"changeRate":-0.10914524805738206,"floatShares":3474486,"shares":3474486,"eps":0,"marketStatus":"已收盘","change":-18.26,"latestTime":"02-05 16:00:00 EST","open":164.43,"high":172.8,"low":147.455,"amount":121585693.92631999,"amplitude":0.151494,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770368400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":167.3,"sharesOutstanding":3424486,"nav":167.537,"aum":573727923.91,"dividendRate":0.009011,"bidAskSpread":0.002126,"preHourTrading":{"tag":"盘前","latestPrice":163.91,"preClose":167.3,"latestTime":"09:29 EST","volume":3823,"amount":633940.0291800001,"timestamp":1770301799999,"change":-3.39,"changeRate":-0.020263,"amplitude":0.029229},"postHourTrading":{"tag":"盘后","latestPrice":147.66,"preClose":149.04,"latestTime":"19:59 EST","volume":11970,"amount":1775237.776,"timestamp":1770339546098,"change":-1.38,"changeRate":-0.009259,"amplitude":0.022209},"volumeRatio":1.268416,"impliedVol":1.0058,"impliedVolPercentile":0.8167},"requestUrl":"/m/hq/s/LABU/tweets","defaultTab":"tweets","newsList":[{"id":"2609536060","title":"【券商聚焦】中信证券：商保有望成为医疗健康产业支付端的核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609536060","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609536060?lang=zh_cn&edition=full","pubTime":"2026-02-06 08:31","pubTimestamp":1770337883,"startTime":"0","endTime":"0","summary":"下一阶段，该机构认为商保综合服务提供商有望解决保司端人才、数据制约，打开创新药械企业创新价值兑现面临的结构性瓶颈，进一步助推商业健康险行业边际加速发展。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974659","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1655091616.SGD","LU2289578879.USD","LABU","LU1997245094.SGD","LU1997245177.USD","LU1720050803.USD","LU1064130708.USD","159760","BK4581","LU0405327494.USD","LU1064131003.USD","BK4588","XLV","LU2495084118.USD","XBI","BK0188","LU1255011170.USD","BK0276","LU0405327148.USD","BK4585","06030","600030","BK1521","BK1516","LU1997244956.HKD","LU1794554557.SGD","BK0028","BK1564","BK0183","LU1328615791.USD","BK0196","BK1147","BK0012"],"gpt_icon":0},{"id":"1125439079","title":"医疗保健板块动态：市场焦点解读","url":"https://stock-news.laohu8.com/highlight/detail?id=1125439079","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125439079?lang=zh_cn&edition=full","pubTime":"2026-02-06 05:52","pubTimestamp":1770328365,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场动态分析。Neuren公司表示，其合作伙伴Acadia Pharmaceuticals近期收到欧洲药品管理局关键委员会的通报，trofinetide的上市许可申请未获支持票。杰富瑞在报告中称：\"基于此消息并保持审慎态度，我们现预计trofinetide在欧盟销售的版权收益将于2026财年第四季度初实现。得益于影像类产品的强劲需求，这家德国医疗企业的市场份额持续扩大。分析师补充道，该公司始终是板块重点推荐标的。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XBI","XLV","LABU","BK4581"],"gpt_icon":0},{"id":"2609884375","title":"爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609884375","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609884375?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:34","pubTimestamp":1770312881,"startTime":"0","endTime":"0","summary":"智通财经APP讯，爱普股份 发布公告，为完善公司战略布局，推动产业链的补强与延伸，实现公司高质量发展，2026年2月4日，公司与挪亚圣诺欧洲签订了《关于挪亚圣诺(太仓)生物科技有限公司之股权收购意向协议》，爱普股份拟受让挪亚圣诺(太仓)生物科技有限公司100% 股权，其中：首次交易即爱普股份受让目标公司80%股权，第二次交易于业绩承诺期满后启动，爱普股份将受让目标公司剩余股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","603020","BK4588","BK0226","LABU","159837"],"gpt_icon":0},{"id":"2609588416","title":"Healthcare Triangle, Inc.盘中异动跌6.40% 换手率达47.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609588416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609588416?lang=zh_cn&edition=full","pubTime":"2026-02-05 23:34","pubTimestamp":1770305648,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日23时34分，Healthcare Triangle, Inc.股票出现波动，股价急速跳水6.40%。Healthcare Triangle, Inc.股票所在的健康信息服务行业中，整体跌幅为1.74%。Healthcare Triangle, Inc.公司简介：Healthcare Triangle Inc 是一家专注于推动行业变革解决方案的医疗信息技术公司，主要关注云服务、数据科学以及医疗和生命科学行业的专业与托管服务领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020523340897a510bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020523340897a510bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","XLV","XBI","LABU","HCTI","BK4581","BK4167"],"gpt_icon":0},{"id":"2609737157","title":"瑞银——美国医疗保健服务行业周度观察（附下载）","url":"https://stock-news.laohu8.com/highlight/detail?id=2609737157","media":"外资精华观点","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609737157?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:42","pubTimestamp":1770277357,"startTime":"0","endTime":"0","summary":"免费体验“高时效”国际投行研报“T+0至T+1”“原研报”可至底部下载瑞银——美国医疗保健服务行业周度观察：医疗人员配置与急性期后护理板块表现突出，美国医疗支出增长，管理式医疗CEO将出席听证会精华翻译 板块表现分化：截至1月16日当周，医疗保健服务类股上涨0.6%，跑赢标普500指数及 broader医疗保健指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161612a47f4a2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161612a47f4a2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0029874061.USD","BK4581","LABU","XBI","BK4588","BK4585","XLV","HCSG","LU0128526141.USD","BK4137"],"gpt_icon":0},{"id":"2609321873","title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321873?lang=zh_cn&edition=full","pubTime":"2026-02-05 14:52","pubTimestamp":1770274343,"startTime":"0","endTime":"0","summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LABU","BK4585","BK4588","159837","BK4134","III"],"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347749?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问，中国不仅已经成为像诺华这样的大型制药公司极为重要的市场，同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日，诺华（NVS.US）首席执行官万思瀚在财报会上表达了上述观点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0211331839.USD","BK4578","BK4588","IE00BJJMRZ35.SGD","BK4007","LU0320765489.SGD","NVS","IE00B4R5TH58.HKD","IE0002141913.USD","LU0208291251.USD","LU0070302665.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4532","159837","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","LABU"],"gpt_icon":0},{"id":"2608138360","title":"生物科技公司PrimeGen将通过15亿美元SPAC交易上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2608138360","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608138360?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:16","pubTimestamp":1770214560,"startTime":"0","endTime":"0","summary":"生物科技公司 PrimeGen US 周三表示，将通过与空白支票公司 DT Cloud Star Acquisition 达成的15 亿美元交易，在美国实现上市。　　该交易预计于2026 年下半年完成。合并后的公司将以 PrimeGen US 名义运营，并计划在纳斯达克交易所挂牌上市。　　此次交易落地之际，企业对通过特殊目的收购公司合并实现上市的兴趣再度升温，将其作为传统上市方式的替代选择。　　PrimeGen 是一家专注于干细胞疗法研发的生物科技公司，主打针对急性肝损伤及相关重症的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-04/doc-inhksktz9552911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","BK4588","LABU","BK4585"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362077?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1100","BK0028","BK0060","BK0096","09997","BK0183","600196","BK0239","01477","BK4585","BK4581","09996","LABU","BK0196","02196","BK1191","BK1574","159883","BK0012","BK0187","XBI","BK0188","159760","XLV","BK1222","BK0175","BK1515","BK1583","BK4588"],"gpt_icon":0},{"id":"2608334457","title":"恒指公司：2025年港股科技与生物科技主题表现突出 恒生双科技指数创下自推出以来最佳表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2608334457","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608334457?lang=zh_cn&edition=full","pubTime":"2026-02-04 13:47","pubTimestamp":1770184057,"startTime":"0","endTime":"0","summary":"恒生科技指数与恒生生物科技指数均于2025年创下年度升幅纪录科技与生物科技领域在2025年受到市场高度关注，相关基准指数的卓越表现充份印证这一点。同时，恒生生物科技指数亦录得64.5%的升幅，为自2019年12月推出以来的最佳年度表现。截至2026年1月30日，恒生双科技指数共有58只成份股，具体数量会因恒生科技指数与恒生生物科技指数之间的重迭程度而有所变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSImain","BK4585","LABU","BK4588","YANG","BK4614","MHImain","159741","HSI","159837","HHImain","513600","02833","MCHmain"],"gpt_icon":0},{"id":"2608273354","title":"Pharmacyte  Biotech, Inc.盘中异动 临近午盘快速下挫5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608273354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608273354?lang=zh_cn&edition=full","pubTime":"2026-02-04 00:32","pubTimestamp":1770136375,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日00时32分，Pharmacyte  Biotech, Inc.股票出现波动，股价大幅下挫5.85%。Pharmacyte  Biotech, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Liminatus Pharma, Inc.涨幅较大，Cdt Equity Inc.、Pmgc Holdings Inc.、Liminatus Pharma, Inc.较为活跃，换手率分别为651.38%、596.88%、57.07%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为70.33%、68.89%、47.28%。Pharmacyte  Biotech, Inc.公司简介：PharmaCyte Biotech Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204003255953fa9ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204003255953fa9ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","PMCB","BK4585","LABU"],"gpt_icon":0},{"id":"2608105438","title":"华金证券：AI医疗健康应用前景广阔 国内AI医疗市场有望高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2608105438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608105438?lang=zh_cn&edition=full","pubTime":"2026-02-03 09:58","pubTimestamp":1770083897,"startTime":"0","endTime":"0","summary":"随着国产AI医疗大模型及医疗器械产品加速获批落地，产业景气度持续向上，为相关企业带来发展机遇。华金证券主要观点如下：AI医疗健康应用前景广阔，应用成熟度有所差异AI技术已经逐步渗透到医疗健康的全产业链，从制药环节的药物研发、临床试验、药物推广，到治疗的诊前、诊中、诊后全生命周期，大大提高医疗服务效率和质量。AI在医药研发中的应用匹配度和可行性较高。技术催化叠加政策推动，国内AI+医疗市场有望迎来高速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","XLV","BK4581","XBI","161027","BK4585","159891","159760","BK4588"],"gpt_icon":0},{"id":"1119569638","title":"医疗保健板块动态：市场对话聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1119569638","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119569638?lang=zh_cn&edition=full","pubTime":"2026-02-03 05:55","pubTimestamp":1770069305,"startTime":"0","endTime":"0","summary":"美国东部时间13:19 - Aquestive Therapeutics股价飙涨44%，尽管美国食品药品监督管理局指出其过敏反应治疗药物Anaphylm舌下膜的申请存在缺陷。该公司表示，FDA的担忧主要涉及包装和管理事项，这些问题应能轻松解决。Cantor分析师Kristen Kluska和Richard Miller表示：\"基本上，我们认为FDA对该审查的安全性和有效性数据包感到满意，但此次确实非常谨慎地进行调整，以避免该产品在紧急情况下被无效使用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","LU0106831901.USD","LU0882574139.USD","LU1720051017.SGD","XBI","BK4585","LU2023251221.USD","LU0098860793.USD","LU0006306889.USD","LU1363072403.SGD","LU2111349929.HKD","BK4588","LU1732800096.USD","LU1720051108.HKD","LU1791710400.SGD","LU1244550494.USD","LU1668664300.SGD","MS","LU0912757837.SGD","LU0267386448.USD","LU0320765646.SGD","LU1732799900.SGD","LU1989772840.SGD","LU2357305700.SGD","BK4127","BK4516","LU0314104364.USD","LU1989772923.USD","LU2133065610.SGD","LU2028103732.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2089284900.SGD","BK4581","IE00BZ1G4Q59.USD","LU0158827781.USD","LU0234570918.USD","LU0557290698.USD","LU2271345857.HKD","BK4534","BK4504","LU0795875086.SGD","LU2089283258.USD","LU1244550577.SGD","LU0795875169.SGD","LU1548497426.USD","LU1162221912.USD","XLV","LU1244550221.USD","LU2347655156.SGD","LU0225283273.USD","LU0106261372.USD","LABU","LU0528227936.USD","LU1791710582.SGD","LU0158827948.USD"],"gpt_icon":0},{"id":"2607076505","title":"职工医保个账共济4.64亿人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2607076505","media":"北京晚报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607076505?lang=zh_cn&edition=full","pubTime":"2026-01-31 14:42","pubTimestamp":1769841720,"startTime":"0","endTime":"0","summary":"本报讯 国家医保局昨天介绍，2025年1月至12月职工医保个人账户共济4.64亿人次，共济金额687.7亿元。　　国家医保局表示，下一步将推动跨省共济使用。　　数据显示，2025年职工基本医疗保险统筹基金收入18317.66亿元，城乡居民基本医疗保险统筹基金收入11226.40亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-31/doc-inhketnc9265897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4581","XLV","BK4588","LABU","BK4585"],"gpt_icon":0},{"id":"2607078581","title":"常德市新增16家省级企业技术中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078581","media":"常德发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078581?lang=zh_cn&edition=full","pubTime":"2026-01-31 08:19","pubTimestamp":1769818740,"startTime":"0","endTime":"0","summary":"值得一提的是，此次全市共有湖南利尔生物科技有限公司、湖南鸿健生物科技有限公司、湖南品六生物科技有限公司3家生物制造相关企业获评省级企业技术中心，彰显常德市合成生物制造核心企业的实力。截至目前，全市累计获评省级企业技术中心112家，认定市级企业技术中心143家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-31/doc-inhkeaqp6338348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2607026245","title":"Purple Biotech Ltd盘中异动 下午盘大幅跳水5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607026245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607026245?lang=zh_cn&edition=full","pubTime":"2026-01-31 03:07","pubTimestamp":1769800050,"startTime":"0","endTime":"0","summary":"北京时间2026年01月31日03时07分，Purple Biotech Ltd股票出现波动，股价快速下跌5.07%。截至发稿，该股报0.592美元/股，成交量5.1986万股，换手率0.58%，振幅3.69%。Purple Biotech Ltd股票所在的生物技术行业中，整体跌幅为0.71%。Purple Biotech Ltd公司简介：Purple Biotech Ltd 是一家临床阶段公司，专注于推进一流疗法以克服肿瘤免疫逃避和耐药性，并为癌症患者创造治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131030730a6c14174&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131030730a6c14174&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LABU","PPBT","BK4585","BK4588"],"gpt_icon":0},{"id":"1112651098","title":"医疗保健板块动态速览：阿斯利康豪掷千亿押注中国减肥药 石药集团股价意外暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1112651098","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112651098?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:24","pubTimestamp":1769765082,"startTime":"0","endTime":"0","summary":"北京时间09:09——麦格理分析师Candyce Gao与Tony Ren在研究报告中指出，阿斯利康正以巨额资金获得中国石药集团旗下早期实验性肥胖症与糖尿病药物组合的授权许可。根据协议，阿斯利康将向石药集团支付12亿美元首付款，若药物达成研发与监管里程碑，后续款项最高可达35亿美元，商业化及销售目标相关的额外付款最高可达138亿美元。阿斯利康股价基本持平，石药集团收盘大跌10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4588","BK4581","BK4585","LABU"],"gpt_icon":0},{"id":"2607009988","title":"慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607009988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607009988?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:55","pubTimestamp":1769756130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma于周四公布其首次公开发行的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass Pharma成立于2019年，计划在纳斯达克挂牌上市，股票代码为“SGP”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","159837","BK4588","BK4585"],"gpt_icon":0},{"id":"2607069375","title":"和谐健康保险总精算师落定，精算老将刘建勋出山","url":"https://stock-news.laohu8.com/highlight/detail?id=2607069375","media":"市场资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607069375?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:58","pubTimestamp":1769738280,"startTime":"0","endTime":"0","summary":"　　近日，和谐健康保险官网更新高管信息，LIU JIANXUN（刘建勋）正式出任公司总精算师。　　据了解，刘建勋是一位年届六旬的行业老将，拥有北美精算师资格，职业生涯横跨中外保险市场。他此次是退休后再度“出山”，此次任命被视为和谐健康在经历长期治理震荡后的“求稳之策”。　　和谐健康保险总精算师一职已空缺近两年。　　而刘建勋的核心任务极为艰巨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyx/2026-01-30/doc-inhizxrr3730555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","LABU","BK4588","BK4581","BK4585","XLV"],"gpt_icon":0},{"id":"2607062845","title":"Definitive Healthcare Corp.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607062845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607062845?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:39","pubTimestamp":1769711956,"startTime":"0","endTime":"0","summary":"北京时间2026年01月30日02时39分，Definitive Healthcare Corp.股票出现波动，股价急速跳水5.08%。截至发稿，该股报2.24美元/股，成交量35.6154万股，换手率0.34%，振幅5.30%。Definitive Healthcare Corp.股票所在的健康信息服务行业中，整体跌幅为1.45%。其相关个股中，Vsee Health Inc C/Wts 、Healthcare Triangle, Inc.、Heartbeam Inc C/Wts 31/10/2026 涨幅较大，Healthcare Triangle, Inc.、Scworx Corp.、Aclarion, Inc.较为活跃，换手率分别为1052.50%、10.34%、10.13%，振幅较大的相关个股有Healthcare Triangle, Inc.、众巢医学、Onemednet Corp，振幅分别为28.14%、23.58%、21.41%。Definitive Healthcare Corp.公司简介：Definitive Healthcare Corp是一家医疗保健商业智能提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130023917a6bcb943&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130023917a6bcb943&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XLV","BK4167","BK4588","LABU","BK4581","XBI","BK4585","DH"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0203},{"period":"1month","weight":0.1004},{"period":"3month","weight":0.4081},{"period":"6month","weight":1.7694},{"period":"1year","weight":0.7583},{"period":"ytd","weight":0.0496}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.012496},{"month":3,"riseRate":0.2,"avgChangeRate":-0.145647},{"month":4,"riseRate":0.4,"avgChangeRate":-0.008819},{"month":5,"riseRate":0.5,"avgChangeRate":0.005207},{"month":6,"riseRate":0.727273,"avgChangeRate":0.127955},{"month":7,"riseRate":0.636364,"avgChangeRate":0.054287},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.004065},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.0652},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}